Engflag

Insulin Protaphane

Quick links to important sections

Insulin Protaphane

Insulin Protaphane_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Insulin Protaphane

Quick Facts

Property Description
Active ingredient Insulin Isophane (NPH Human Insulin)
Form Suspension for injection
Pharmacological class Antidiabetic agent / Hypoglycemic agent
Functional type Intermediate-acting basal insulin
Origin Biosynthetic (Recombinant DNA technology)
Manufacturer/Status Prescription-only medicine, Novo Nordisk

What Type of Medicine is Insulin Protaphane?

Protaphane is a trade name for a medicinal preparation containing the active substance Insulin Isophane, which functions as an antidiabetic agent and a hypoglycemic agent. It is clinically recognized as an intermediate-acting insulin that serves as a basal insulin, providing a necessary, sustained background level of activity to regulate blood sugar.

This preparation belongs to the pharmacological class of Insulin preparations and its fundamental purpose is to help the body manage the concentration of glucose in the bloodstream. Because it provides a sustained effect, it is typically used to ensure consistent glucose control during the longer periods between meals and throughout the night, supporting overall metabolic function.

Protaphane's Composition, Origin, and Form

The active ingredient, Insulin Isophane (Neutral Protamine Hagedorn, NPH), is Human Insulin that is produced via recombinant DNA technology, confirming its status as a high-purity biosynthetic product. Its distinctive form is a slightly cloudy suspension for injection, rather than a clear solution.

This unique form results from combining the Human Insulin with protamine and zinc, forming a stable, crystalline complex within an aqueous vehicle. This specific formulation ensures the insulin is absorbed gradually following its parenteral (subcutaneous) administration. The controlled release mechanism defines its intermediate duration of action and differentiates it structurally from both rapid-acting insulins and peakless long-acting analogues.

Understanding Its General Purpose as a Sustained Metabolic Regulator

The general purpose of Protaphane is to maintain consistent and foundational blood sugar control over an extended period, promoting overall metabolic stability. It achieves this by performing two primary actions: facilitating the uptake of circulating glucose by the body’s cells for energy or storage, and simultaneously reducing the production and release of stored glucose by the liver. By consistently providing this basal regulatory effect for many hours, Protaphane helps to balance the body's continuous energy demands.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Insulin Protaphane?

Possible Side Effects and Safety Information

The safety profile of Insulin Protaphane (Insulin Isophane) is primarily defined by the therapeutic effect of lowering blood glucose. This section details the adverse reactions and safety characteristics as officially documented in regulatory information.

Frequency-Classified Adverse Reactions

The most frequent safety concern is hypoglycaemia (low blood sugar), which is officially classified as a Very Common adverse reaction, meaning it may affect more than 1 in 10 individuals. Other common occurrences include local reactions at the injection site, such as swelling, redness, or itching.

Less common side effects, typically classified as Uncommon, may involve the skin and subcutaneous tissue, such as lipodystrophy (changes in fat tissue at the injection site), and generalized hypersensitivity reactions, including rash or hives. Transient peripheral oedema (swelling) is also documented in this category.

Serious Adverse Reactions

The most serious, though rare, safety concern documented is a Very Rare occurrence of anaphylactic reactions. This is classified as a severe, systemic, immediate-type hypersensitivity reaction affecting the immune system.

Contextual Safety Patterns

Certain adverse reactions are noted to be time-dependent. For instance, temporary refraction anomalies (visual disturbances) are often observed when treatment is initiated and tend to resolve over time. Lipodystrophy is associated with long-term exposure, specifically when the injection site is not rotated adequately.

Safety Considerations for Special Populations

Official labeling includes safety notes for patients with pre-existing conditions. Individuals with renal or hepatic impairment may require a reduced insulin dose, a safety consideration documented due to the increased potential for hypoglycaemia related to altered insulin clearance or metabolism.

Overdose and Emergency Response

Overdose and When to Seek Help

Insulin Protaphane overdose is officially defined not by a specific dose amount but as the administration of too much insulin relative to the patient's requirement, resulting in hypoglycaemia (low blood sugar).

Documented Overdose Manifestations

The primary clinical manifestation is hypoglycaemia, which typically develops over sequential stages. Physiological systems primarily affected include the metabolic system and the central nervous system, which can be impaired in severe cases.

Required Emergency Actions

The regulatory-mandated response is dependent on the severity of the low blood sugar episode:

  • Mild Episodes: Can often be self-treated by the oral administration of glucose, sugary products, or sugary fruit juice. Patients are officially advised to always carry readily available sugar.
  • Severe Episodes: If the patient becomes unconscious due to severe hypoglycaemia, immediate emergency medical intervention is required. Treatment is typically administered by a trained person or healthcare professional, using an injection of glucagon (intramuscularly or subcutaneously).

When to Seek Immediate Medical Help

Immediate medical assistance must be sought if the patient is unconscious. Furthermore, intravenous glucose must be given by a medical professional if the patient does not respond to the initial administration of glucagon within 10 to 15 minutes.

Therapeutic Uses of Insulin Protaphane

What Insulin Protaphane Treats: Main Uses and Benefits

Insulin Protaphane is an intermediate-acting human insulin used to manage blood glucose levels in individuals with diabetes mellitus. It is designed to provide a steady basal level of insulin, helping to maintain glycemic control over an extended period.

Main Uses

The primary use of Insulin Protaphane is the treatment of diabetes mellitus, a condition characterized by high blood sugar resulting from the body's inability to produce or properly use insulin. It is used in the following contexts:

  • Type 1 Diabetes: In individuals with type 1 diabetes, the pancreas produces little to no insulin. Insulin Protaphane serves as a replacement for the basal insulin the body is unable to produce.
  • Type 2 Diabetes: For individuals with type 2 diabetes, the body may not produce enough insulin or may become resistant to its effects. This insulin is used when oral medications or other treatments are insufficient to maintain target blood sugar levels.
  • Combination Therapy: It is often used in a "basal-bolus" regimen, where it provides the background (basal) insulin coverage, while fast-acting insulins are used to manage blood sugar spikes during meals.

Mechanism of Action

As an isophane (NPH) insulin, Insulin Protaphane contains protamine and zinc, which slow down its absorption into the bloodstream. Once injected, it begins to lower blood sugar within approximately 1.5 hours, reaches its peak effect between 4 and 12 hours, and continues to work for up to 24 hours. This profile allows for a prolonged glucose-lowering effect compared to short-acting insulins.

Key Benefits

The therapeutic goal of using Insulin Protaphane is to achieve stable blood glucose levels, which is essential for long-term health management. The benefits include:

  • Extended Glycemic Control: Its intermediate duration of action helps bridge the gaps between meals and provides coverage throughout the night.
  • Predictable Basal Support: By mimicking a portion of the natural background insulin secretion, it helps prevent hyperglycemia during periods of fasting.
  • Prevention of Complications: Consistent management of blood glucose levels is a fundamental factor in reducing the risk of long-term complications associated with diabetes, such as damage to the kidneys, eyes, nerves, and cardiovascular system.

Regulatory References

  1. Protaphane EPAR Summary of Product Characteristics

Eligibility and Restrictions for Use

Who Can and Cannot Use Insulin Protaphane?

The population eligibility for Insulin Protaphane (Isophane Human Insulin) is strictly defined by regulatory documents, outlining both absolute prohibitions and conditions for use.

Absolute Contraindications (Cannot Use)

Protaphane is contraindicated and must not be used by the following groups:

  • Patients with known hypersensitivity to the active substance (human insulin) or to any of the excipients in the formulation.
  • Patients currently experiencing an episode of hypoglycaemia.

Eligibility and Restrictions (Can Use)

Population Group Official Eligibility Status
Age Groups Permitted for use in the paediatric population (children and adolescents), adults, and elderly patients (≥ 65 years).
Pregnancy/Lactation Permitted during both pregnancy and breastfeeding; intensified glucose monitoring is recommended during pregnancy.
Organ Impairment Permitted with caution; patients with renal impairment or hepatic impairment require intensified glucose monitoring and individualized dose adjustment due to altered insulin requirements.

Eligibility for Protaphane is established across all age groups but is restricted by the absolute requirement to avoid injection during a hypoglycaemic state.

What should I know about interactions with other medicines?

The interaction profile for Insulin Protaphane (Insulin Isophane NPH) is defined by its effects on blood glucose control and specific pharmaceutical constraints, as documented by regulatory authorities.

Pharmacodynamic Interactions

Medicines that may reduce the patient's insulin requirement—thereby enhancing the blood glucose-lowering effect—include Oral Antidiabetic Products, MAOIs, ACE Inhibitors, Salicylates, Anabolic Steroids, and Sulfonamides. Conversely, a number of agents may increase the patient's insulin requirement, including Oral Contraceptives, Glucocorticoids, Thyroid Hormones, Sympathomimetics, and Danazol. The co-administration of Beta-blockers is documented to have a pharmacodynamic effect that may mask the symptoms of hypoglycemia. Furthermore, the combination with Thiazolidinediones (TZDs), such as Pioglitazone, is associated with a labeled systemic risk of fluid retention and heart failure.

Substance and Handling Constraints

Consumption of alcohol is officially documented to have a bi-directional effect, potentially intensifying and prolonging or reducing the hypoglycaemic effect. The regulatory profile includes strict restrictions on preparation: this suspension must not be diluted or mixed with other insulins or solutions, apart from Regular Human Insulin, to prevent altering the pharmacokinetic and pharmacodynamic profile. The medication is formally contraindicated during episodes of hypoglycemia. Additionally, patients with renal or hepatic impairment are noted as potentially requiring an adjustment to their insulin requirement due to altered clearance.

Mechanism of Action

Insulin Protaphane (isophane human insulin) is a suspension formulated with protamine and zinc to create a crystalline complex. Following subcutaneous injection, the protamine-insulin complex dissolves gradually, releasing the active insulin molecule into systemic circulation at a sustained rate. This mechanism of delayed absorption provides an intermediate-acting pharmacological profile.

The released insulin acts as an agonist by binding to the cell-surface, heterotetrameric Insulin Receptor (IR), a receptor tyrosine kinase, primarily on target tissues including skeletal muscle, adipose tissue, and hepatocytes. This binding induces receptor beta-subunit autophosphorylation and the recruitment and phosphorylation of intracellular substrates, such as Insulin Receptor Substrate (IRS) proteins.

Downstream cascades proceed through the PI3K-Akt pathway. Akt activation facilitates the translocation of intracellular vesicles containing Glucose Transporter type 4 (GLUT4) to the plasma membrane of muscle and adipose cells. This action increases the permeability of the cell membrane to glucose. Concurrently, insulin signaling modulates hepatic enzyme activity by inhibiting gluconeogenesis and glycogenolysis via suppression of transcription factors like FOXO1, while promoting glycogenesis and lipogenesis.

System-level physiological consequences include the redistribution of glucose from the systemic circulation into insulin-sensitive peripheral tissues and the suppression of endogenous glucose production by the liver.

Dosage and Administration Information

Protaphane is an intermediate-acting insulin suspension that must be administered as a subcutaneous injection only; it is never to be administered intravenously or used in insulin infusion pumps. The dosage is strictly individualized by the physician, with a typical total daily insulin requirement falling within the range of 0.3 to 1.0 International Units (IU) per kg of body weight. Protaphane may be used alone or mixed with a fast-acting insulin, commonly serving as basal insulin with a frequency of once or twice a day (evening and/or morning injection).

Administration Procedure

Classification Rule
Route Subcutaneous injection in the thigh (preferred), abdominal wall, gluteal, or deltoid region.
Preparation The suspension is cloudy and white and must be resuspended immediately before use by rolling or inverting the device until the liquid appears uniformly cloudy.
Injection Technique Inject into a lifted skin fold to minimize the risk of unintended intramuscular injection. Keep the needle under the skin for at least six seconds to ensure the full dose is delivered.
Site Management Injection sites must be rotated within the same anatomical region (e.g., thigh) to reduce the risk of lipodystrophy.

Missed and Special Use Rules

Patients must be instructed to check the insulin label before each injection to prevent accidental mix-ups with other insulin products. If a dose is missed or an inadequate dose is injected, hyperglycemia (high blood sugar) may occur; patients must not stop treatment unless directed by a doctor. Protaphane is suitable for use in elderly patients (≥ 65 years old), but dosage may require adjustment for all age groups, such as during periods of illness or increased physical activity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Insulin Protaphane

Evidence for Use in Type 1 Diabetes Mellitus

Research has primarily focused on NPH human insulin as a basal, or background, insulin within clinical trials for individuals with Type 1 Diabetes. These investigations typically involve Randomized Controlled Trials (RCTs) and Systematic Reviews that explored the measurement of specific changes in blood sugar control, often comparing NPH to newer insulin formulations. The outcomes related to systemic or functional imbalance that were monitored included standard measures like average blood sugar over two to three months (Glycosylated Hemoglobin or HbA1 c) and Fasting Plasma Glucose.

The research highlights changes measured during the study period, particularly for these short-term biomarkers. Studies explored the frequency and classification of episodic or acute changes in blood sugar, focusing especially on low blood sugar events (hypoglycemia), which was a focus of comparison studies, with some reporting differences in nighttime event rates versus alternative treatments. Findings describe patterns observed in the studies across both adult and pediatric populations with this condition.

Evidence for Use in Type 2 Diabetes Mellitus

NPH human insulin has been evaluated in clinical studies for managing Type 2 Diabetes, frequently in combination with oral medications used alongside insulin. The research structure consists of numerous Randomized Controlled Trials and subsequent analyses like Systematic Reviews and Meta-analyses. These studies monitored outcomes related to systemic or functional imbalance such as HbA1 c and Fasting Blood Glucose, and also included assessments of body weight changes and the frequency of low blood sugar events.

The data show patterns related to the measured changes in short-term blood sugar markers in the populations observed, which generally included adults beginning insulin therapy or needing to intensify their treatment. The key limitation is that there is limited information for long-term outcomes linked to cardiovascular health or the prevention of chronic microvascular or macrovascular complications. The research typically explored short-term symptom changes, and the majority of trials were not designed to collect data over the many years required to assess these long-term effects.

Evidence in Special Populations

The research has explored the use of NPH human insulin in several specific groups. This includes studies in children and adolescents, specific trials that monitored the use of NPH in older adults with Type 2 Diabetes, and reviews of evidence for Gestational Diabetes Mellitus (GDM). However, data for certain groups remain insufficient, and the overall evidence quality varies across studies due to the diverse nature of the trials included in systematic reviews.

What Research Gaps and Uncertainty Remain

Key research limitation frames apply to the existing evidence base. Certainty remains low for long-term health outcomes, as dedicated, multi-year trials focusing on events like heart attacks, stroke, or mortality are generally lacking. Sample sizes were modest in many trials, limiting the ability to draw definitive conclusions about specific subgroup findings.

Frequently Asked Questions (FAQ)

Common questions about Insulin Protaphane (FAQ)

Q: How quickly does Insulin Protaphane start working and how long does it last?

Insulin Protaphane is classified as an intermediate-acting insulin. According to official product information, the onset of action, which is when the blood sugar-lowering effect begins, typically occurs 1 to 3 hours after injection. The medication is designed to provide a prolonged effect, with a total duration of action that can last for up to 24 hours.

Q: Does Insulin Protaphane come in a vial, a pen, or both?

Official regulatory information indicates that this medicine is supplied in various formats for injection. It is available as a suspension in vials, cartridges (Penfill), and as a suspension in pre-filled pens (such as FlexPen and InnoLet). The specific formats available may vary depending on the local brand and country.

Q: Will taking this medication stop me from being able to drive or operate machinery?

Official warnings note that an episode of hypoglycemia (low blood sugar), a common side effect of insulin, can temporarily impair concentration and reaction time. This presents a safety consideration in situations such as driving or operating machinery. Caution is advised when engaging in these activities, especially for patients who experience frequent low blood sugar or reduced awareness of their hypoglycemia warning signs.

Q: Is it possible for my body to become resistant to Insulin Protaphane over time?

Rarely, insulin therapy can result in the body producing insulin antibodies. This is known as immunological insulin resistance, which can develop in patients with very high titers of IgG-antibodies. These antibodies can potentially reduce the effectiveness of the insulin.

How should Insulin Protaphane be stored and disposed of?

Official Storage and Disposal Requirements

Protaphane (Insulin Isophane) is subject to strict regulatory requirements to maintain its stability. All storage and disposal rules are defined by official labeling and are mandatory.

Condition Requirement
Unopened Storage Must be kept refrigerated (2°C to 8°C).
Prohibited Storage Must not be frozen; frozen insulin must be discarded.
In-Use Storage Store below 25°C or 30°C (temperature varies by presentation) for a limited period (e.g., 4 to 6 weeks).
Protection Rule Must be kept in the original outer carton to protect it from light and excessive heat.
Child Safety Mandatory to keep out of the sight and reach of children.
Disposal Unused or expired product and waste material must be disposed of according to local regulatory requirements. Used needles (sharps) must be safely placed in a puncture-proof container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Insulin Protaphane found in:

A-Z Index: